Qsemble Capital Management, LP Crispr Therapeutics Ag Transaction History
Qsemble Capital Management, LP
- $751 Billion
- Q4 2024
A detailed history of Qsemble Capital Management, LP transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Qsemble Capital Management, LP holds 17,664 shares of CRSP stock, worth $699,847. This represents 0.09% of its overall portfolio holdings.
Number of Shares
17,664Holding current value
$699,847% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding CRSP
# of Institutions
493Shares Held
59.4MCall Options Held
1.09MPut Options Held
1.9M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.97MShares$356 Million3.09% of portfolio
-
Capital International Investors Los Angeles, CA7.93MShares$314 Million0.07% of portfolio
-
State Street Corp Boston, MA2.99MShares$119 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$110 Million0.0% of portfolio
-
Nikko Asset Management Americas, Inc.2.75MShares$109 Million1.21% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.09B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....